KNSA Q1 2021 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$883,000

Operating Income

-$49M

Net Income

-$49M

EPS (Diluted)

$-0.72

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$60M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$311M

Total Liabilities

$40M

Stockholders' Equity

$271M

Cash & Equivalents

$120M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$883,000	$0	—
Operating Income	-$49M	-$29M	-67.7%
Net Income	-$49M	-$26M	-87.3%